Cancer Research in Switzerland - Krebsliga Schweiz

More documents

Recommendations

Info

154 Heinimann Karl | KFS 02489-08-2009 | CHF 133,000.– Forschungsgruppe Humangenetik, Abteilung für medizinische Genetik UKBB, Departement Biomedizin, Universität Basel, Basel miRNA expression profiling in Lynch syndrome-associated colorectal cancer Körner Meike | OCS 02349-02-2009 | CHF 108,500.– Abteilung für Zellbiologie und experimentelle Krebsforschung, Institut für Pathologie, Universität Bern, Bern In vitro evaluation of the glucagon-like peptide 2 receptor expression in human cancer: molecular basis for in vivo tumor radiotargeting Kristiansen Glen | KFS 02465-08-2009 | CHF 171,200.– Institut für klinische Pathologie, UniversitätsSpital Zürich, Zürich Identification of a clinically applicable prognostic RNA signature of prostate cancer Mermod Nicolas | KFS 02446-08-2009 | CHF 360,100.– Laboratoire de biotechnologie moléculaire, Institut de biotechnologie, Université de Lausanne, Lausanne Evaluation of AP2 protein-binding microarrays for breast tumor profiling and for the prognosis of the response to chemotherapies Moeckli Raphaël | KFS 02637-08-2010 | CHF 107,200.– Institut de radiophysique, Département de radiologie, Centre hospitalier universitaire vaudois (CHUV), Lausanne Evaluation of second cancer risk models in radiotherapy for average and high dose levels Müller Beatrice U. | KFS 02449-08-2009 | CHF 297,900.– Departement für allgemeine Innere Medizin und klinische Forschung, Inselspital, Bern Transcriptional dysregulation during myeloid transformation in acute myeloid leukemia (AML) Nadal David | KLS 02375-02-2009 | CHF 227,900.– Abteilung Infektiologie und Spitalhygiene, Medizinische Klinik, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich Is endemic Burkitt’s lymphoma really promoted by chronic innate immunity triggering by malaria infection? Niggli Felix | KLS 02578-02-2010 | CHF 298,300.– Onkologielabor, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich Constitution of a national study centre for the European acute lymphoblastic leukaemia trial (AIEOP-BFM ALL 2009) on behalf of the Swiss paediatric oncology group (BFM-CH) Ozsahin Hulya | KLS 02656-08-2010 | CHF 155,300.– Unité d’onco-hématologie pédiatrique, Hôpitaux universitaires de Genève (HUG), Genève SIOPEL International Childhood Liver Tumour Strategy Group – a comprehensive research program and a randomized trial for standard risk hepatoblastoma Pabst Thomas | KLS 02520-02-2010 | CHF 349,100.– Institut für medizinische Onkologie, Inselspital, Bern Transcriptional dysregulation of the myeloid key transcription factor CEBPA in human acute myeloid leukemia Petignat Patrick | KFS 02691-08-2010 | CHF 230,600.– Unité d’oncogynécologie chirurgicale, Hôpitaux universitaires de Genève (HUG), Genève Self-sampling for HPV in women who do not undergo routine cervical cancer screening: A randomized trial Renevey Philippe | KFS 02681-08-2010 | CHF 138,400.– Centre suisse d’électronique et de microtechnique (CSEM), Neuchâtel Automatic vocal aid system for laryngectomees with improved voice quality Resink Theresa | KFS 02447-08-2009 | CHF 343,000.– Forschungsgruppe Signaltransduktion, Departement Biomedizin, Universität Basel, Basel T-cadherin: a functional determinant and early prognostic marker for malignant transformation of squamous cell carcinomas Roth Arnaud | KFS 02697-08-2010 | CHF 202,700.– Unité d’oncochirurgie, Hôpitaux universitaires de Genève (HUG), Genève Molecular heterogeneity and prognostic markers in colon cancer by analysis of gene expression and gene mutation data
Rothermundt Christian | KFS 02641-08-2010 | CHF 76,500.– Fachbereich Onkologie/Hämatologie, Kantonsspital St. Gallen, St. Gallen Metformin in castration resistant prostate cancer. A multicenter phase II trial of the SAKK (Swiss Group for Clinical Cancer Research) (SAKK08/09) Rufer Nathalie | KFS 02635-08-2010 | CHF 210,300.– Centre Ludwig de recherche sur le cancer, Université de Lausanne, Lausanne Structural and functional studies of T-cell receptors specific for tumor antigens: Implications for immunotherapy in cancer patients Schwaller Jürg | OCS 02357-02-2009 | CHF 232,000.– Forschungsgruppe Kinder-Leukämie, Departement Biomedizin, Universitätsspital Basel, Basel Exploring new molecular therapeutic targets in MLL-X acute leukemia Skoda Radek | KLS 02398-02-2009 | CHF 324,100.– Forschungsgruppe experimentelle Hämatologie, Departement Biomedizin, Universität Basel, Basel The pathogenesis of myeloproliferative disorders Stenner-Liewen Frank | KFS 02423-04-2009 | CHF 216,700.– Medizinische Onkologie, UniversitätsSpital Zürich, Zürich Establishment of GOLPH2 as a serum marker in hepatocellular carcinoma (within the SAKK 77/08 trial) and in bile duct cancer for routine clinical use Zeller Rolf | OCS 02368-02-2009 | CHF 360,350.– Forschungsgruppe Entwicklungsgenetik, Departement Biomedizin, Universität Basel, Basel Functional analysis of modulators of SHH pathway activity during the formation of medulloblastomas: a mechanistic study with clinical relevance Approved bursaries in 2009/2010 Total funds allocated: CHF 621,250.– Arber Barth Caroline | BIL KFS 02506-08-2009 | CHF 109,300.– Targeting B acute lymphoblastic leukemia by adoptive transfer of leukemia-specific T-cells after cord blood transplantation Zielort: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, USA Baumann Michael | BIL KLS 02589-02-2010 | CHF 28,750.– Treatment of naive and fludarabine-refractory CLL in the TCL-1 mouse model with IPI-926 and other hedgehog pathway inhibitors Zielort: Labor für molekulare Biologie und Immunologie der CLL, Klinik I für Innere Medizin, Universität Köln, Köln, Deutschland Bohanes Pierre | BIL KLS 02591-02-2010 | CHF 53,500.– Intratumoral gene expression and germline polymorphism of patients with gastric cancer treated with chemoradiation in the Southwest Oncology Group protocol (SWOG) 9008 Zielort: USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA Dedes Konstantin | BIL KLS 02406-02-2009 | CHF 60,000.– Identification of therapeutic targets for invasive ductal carcinomas of no special type Zielort: Breakthrough Breast Cancer Research Center, Institute of Cancer Research and the Royal Marsden Hospital, London, United Kingdom Omlin Aurelius | BIL KFS 02592-02-2010 | CHF 136,000.– A prospective comparison of three different methods of circulating tumor cell (CTC) isolation and characterization utilizing multi-colour immunofluorescence (IF) and fluorescent in-situ hybridization (FISH) in advanced cancer patients Zielort: Drug Development Unit, Royal Marsden Hospital, Sutton Surrey, United Kingdom 155
Page 1 and 2:
Cancer Research in Switzerland A pu
Page 3 and 4:
Cancer Research in Switzerland
Page 5 and 6:
Basic biomedical research 55 Cancer
Page 7 and 8:
policy work and was in charge of de
Page 9 and 10:
The main focus of the research fund
Page 11 and 12:
gramme research funding decreased b
Page 13 and 14:
Table 2 Distribution of funds for i
Page 15 and 16:
Funding patient-centred research Pa
Page 17 and 18:
value was not clearly discernible.
Page 19 and 20:
New organization of the Foundation
Page 21 and 22:
The board of the Foundation Cancer
Page 23 and 24:
The president of the Scientific Com
Page 25 and 26:
Prof. Martin Pruschy, PhD Departmen
Page 27 and 28:
Swartz wants to find out how tumour
Page 29 and 30:
The scientific and medical research
Page 31 and 32:
3. The original order/sequence of t
Page 33 and 34:
As a federation, the Cancer League
Page 35 and 36:
List of funded research projects, i
Page 37 and 38:
Zippelius Alfred | 2009: CHF 100,00
Page 39 and 40:
Kridel Robert | 2010: CHF 100,000.-
Page 41 and 42:
Thurgau Cancer League Biotechnologi
Page 43 and 44:
Weller Michael | 2010: CHF 65,828.-
Page 45 and 46:
manageable funding of individual pr
Page 47 and 48:
enhances breast cancer cell motilit
Page 49 and 50:
Rüegg Curzio et al. | Tumor-mediat
Page 51 and 52:
International Clinical Cancer Resea
Page 53 and 54:
in PHIV were shown for Hodgkin’s
Page 55:
Zucca Emanuele et al. | Internation
Page 58 and 59:
56 “hierarchical structure” of
Page 60 and 61:
58 the attempt should be made to st
Page 62 and 63:
60 Gönczy Pierre | KLS 0202402
Page 64 and 65:
62 Romero Pedro | OCS 020110220
Page 66 and 67:
64 Beermann Friedrich | In vivo scr
Page 68 and 69:
66 Christofori Gerhard | Podoplanin
Page 70 and 71:
68 Frei Christian | The function of
Page 72 and 73:
70 cell, this novel mechanism serve
Page 74 and 75:
72 Results The induction of viral p
Page 76 and 77:
74 Hübscher Ulrich | Repair of oxi
Page 78 and 79:
76 Methods and experimental approac
Page 80 and 81:
78 of cMyc and/or NMyc and demo
Page 82 and 83:
80 In summary, this work improves o
Page 84 and 85:
82 Pruschy Martin | Microtubule int
Page 86 and 87:
84 Renner Christoph | Selective inh
Page 88 and 89:
86 Goal Here we build on these obse
Page 90 and 91:
88 by TDG prevents efficient downst
Page 92 and 93:
90 To address these questions, we a
Page 94 and 95:
92 Translational relevance The resu
Page 96 and 97:
94 Grünberg Jürgen | KFS 025460
Page 98 and 99:
96 Tschan Mario P. | KFS 0248608
Page 100 and 101:
98 Boyman Onur | Preclinical testin
Page 102 and 103:
100 Constam Daniel | Role of activi
Page 104 and 105:
102 this study we will examine the
Page 106 and 107: 104 Janscak Pavel | Study of the ro
Page 108 and 109: 106 Müller Anne | The molecular pa
Page 110 and 111: 108 Radtke Freddy | The role of Not
Page 112 and 113: 110 Schär Primo | DNA repair, epig
Page 114 and 115: 112 In this project we will investi
Page 116 and 117: 114
Page 118 and 119: 116 and Research). Other financial
Page 120 and 121: 118 be totally unaffordable for aca
Page 122 and 123: 120 Clinical research List of compl
Page 124 and 125: 122 Hunger Robert E. | OCS 02262-08
Page 126 and 127: 124 Clinical research Presentation
Page 128 and 129: 126 Benhattar Jean | Identification
Page 130 and 131: 128 Bertoni Francesco | Genome-wide
Page 132 and 133: 130 Interpretation ESA treatment in
Page 134 and 135: 132 Our results could pave the way
Page 136 and 137: 134 new drugs that specifically tar
Page 138 and 139: 136 slides in two different concent
Page 140 and 141: 138 Conclusions A strong network of
Page 142 and 143: 140 tions introduced to ARE motifs
Page 144 and 145: 142 Müller Beatrice U. | The maste
Page 146 and 147: 144 A novel method was developed fo
Page 148 and 149: 146 (SAKK 35-98) the Swiss Group fo
Page 150 and 151: 148 Timmermann Beate | Prospective
Page 152 and 153: 150 recurrence of the disease, we a
Page 154 and 155: 152 Zucca Emanuele | A prospective
Page 158 and 159: 156 Riggi Nicolò | BIL KFS 02717-0
Page 160 and 161: 158 activity at the single cell lev
Page 162 and 163: 160 Our research projects aim at un
Page 164 and 165: 162 Körner Meike | In vitro evalua
Page 166 and 167: 164 Nadal David | Is endemic Burkit
Page 168 and 169: 166 (> 50.000/patient). For their a
Page 170 and 171: 168 Zeller Rolf | Functional analys
Page 172 and 173: 170
Page 174 and 175: 172 area of health services researc
Page 176 and 177: 174 The financing of palliative car
Page 178 and 179: 176 National Strategy for Palliativ
Page 180 and 181: 178 Psychosocial research List of c
Page 182 and 183: 180 Within the patient group, level
Page 184 and 185: 182 Further, the results suggest th
Page 186 and 187: 184 It is in this context that the
Page 188 and 189: 186 Recommendation Female spouses o
Page 190 and 191: 188 Psychosocial research Presentat
Page 192 and 193: 190 rates communication skills rema
Page 195 and 196: Epidemiological research Epidemiolo
Page 197 and 198: data from cancer registries. In the
Page 199 and 200: The importance of cancer registries
Page 201 and 202: Ess Silvia | Patterns of care and s
Page 203 and 204: Epidemiological research List of ap
Page 205 and 206: Impact This work will serve as the
Page 207 and 208:
Thürlimann Beat | Management of br
show all

Cancer Research in Switzerland - Krebsliga Schweiz

Create successful ePaper yourself

Delete template?

Save as template?